6th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, 18-19 February 2010, Geneva
Selected presentations
WHO disclaimer:
The designations employed and the presentation of the material on the web only represents the views of the authors and do not imply the expression of any opinion whatsoever on the part of the World Health organization concerning the legal status of any country, territory, city or area or of its authorities.
The World Health organization does not warrant that the information contained in this material is complete and correct and shall not be liable for any damages incurred as a result of its use.
18 February 2010
-
Development of candidate H1N1 vaccine viruses and evolution of H1N1 viruses - Alexander Klimov
pdf, 1.18Mb -
Update on H1N1 vaccine trials, CSL Australia - Terry Nolan
pdf, 587kb -
Summary on H1N1 vaccine in China: state manufacturers - Ze Chen
pdf, 650kb -
Summary on H1N1 vaccine in China: Sinovac - Yong Zou
pdf, 1.13Mb -
H1N1 vaccine development in Russia - Igor Krasilnikov
pdf, 292kb -
H1N1 clinical trials’ results in Korea - Byung Geon Rhee
pdf, 15.84Mb -
Update on H1N1 vaccine development, Sanofi Pasteur - Martine Denis
pdf, 481kb -
Update on clinical trials of GSK pandemic influenza - Dirk Campens
pdf, 1.07Mb -
2009 H1N1 co- and sequential administration with TIV - Sharon Frey
pdf, 294kb -
H1N1 vaccines in Hungary, Omnivest - Gyorgy Fazekas
pdf, 1.07Mb -
Evaluation of H1N1 vaccine in phase 1 trial, Cantacuzino, Romania - Dr Roxana Dimitriu
pdf, 467kb -
Clinical evaluation of H1N1 and H5N1 vaccines in Japan - Masato Tashiro
pdf, 1.18Mb
19 February 2010
-
A Phase II safety and immunogenicity study of different clades and schedules of H5N1 unadjuvanted, subvirion influenza vaccines - Mark Mulligan
pdf, 1.69Mb -
Update on Vero cell-derived pandemic vaccines, Baxter - Otfried Kistner
pdf, 427kb -
Safety and immunogenicity of cell- derived whole virus H5N1 vaccine in phase 2, Vabiotech, Vietnam - Nguyen Thu Van
pdf, 333kb -
LAIV H1N1 vaccine evaluation, Medimmune - Kathy Coelingh
pdf, 159kb -
H1N1, Microgen and Inst. Exp. Medicine, Russia - Larisa Rudenko
pdf, 697kb -
New H1N1 LAIV developments. Serum Institute of India, India - Prasad Kulkarni
pdf, 74kb -
Evaluation of H1N1 LAIV in phase 1 trial, GPO, Thailand - Punnee Pitisuttithum
pdf, 3.81Mb -
Clinical evaluation of H5N1 Δ NS1 intranasal influenza vaccine - Andrej Egorov
pdf, 780kb -
Results from Novavax phase 2 safety and immunogenicity study of an A (H1N1) 2009 influenza virus-like particle (VLP) vaccine in Mexico - Maria Allende
pdf, 1.48Mb -
Phase 1 clinical trial of PaxVax live, oral Ad4-vectored H5N1 vaccine - Kenneth Kelley
pdf, 59kb -
Overview of clinical studies conducted with monovalent pandemic rHA (H5 and H1) - Manon Cox
pdf, 455kb -
Update on development and evaluation of VLP-based H5N1 vaccine produced in plants, Medicago Inc. - Nathalie Landry
pdf, 2.03Mb -
Recommendations of the SAGE meeting on vaccination against H1N1 pandemic - David Salisbury
pdf, 667kb -
Update on standardization of immunological methods for assessment of immunogenicity of pandemic vaccines - John Wood
pdf, 291kb -
Lessons learned on regulatory preparedness - David Wood
pdf, 184kb -
Safety of pandemic vaccination - Dina Pfeifer
pdf, 464kb -
Effectiveness of pandemic vaccination - Maria Zambon
pdf, 395kb